Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C.sub.max) of at least 30 ng/mL, with (b) a mean time to C.sub.max (T.sub.max) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

The present disclosure relates to a method for preparing biocompatible polymer-based Apixaban-loaded microspheres. More specifically, the present disclosure relates to a method for preparing biocompatible polymer-based Apixaban-loaded microspheres, where the method includes: i) adding a fatty acid or triglyceride to a dispersed phase; and ii) preparing microspheres using a microfluidic method. The method for preparing biocompatible polymer-based Apixaban-loaded microspheres of the present disclosure may be effectively used in the preparation of microspheres in which Apixaban is stably encapsulated in high contents.

The present disclosure relates to a composition of dispersed phase for the preparation of Apixaban-loaded microspheres and biocompatible polymer-based Apixaban-loaded microspheres prepared therefrom. Specifically, the present disclosure relates to a composition of dispersed phase for the preparation of Apixaban-loaded microspheres, where the composition includes i) Apixaban or a pharmaceutically acceptable salt thereof; ii) a biocompatible polymer; iii) a fatty acid or triglyceride; and iv) a halogen organic solvent; and biocompatible polymer-based Apixaban-loaded microspheres. The composition of dispersed phase for the preparation of Apixaban-loaded microspheres shows excellent stability and thus may be useful for the preparation of Apixaban-loaded microspheres. Additionally, the biocompatible polymer-based Apixaban-loaded microspheres may be contained in pharmaceutical compositions to be used as a therapeutic agent, because the Apixaban may be stably encapsulated therein in high contents and the initial drug release thereof may be suppressed.

The solubility and bioavailability properties of meloxicam can be improved by preparing compositions of meloxicam co-crystals and reducing the particle size of (e.g., “nanosizing”) co-crystals. Such compositions with improved dissolution pharmacokinetic properties can be prepared by granulation and blending the co-crystals with extragranular excipients to provide oral solid dosage forms. As a result of the improved properties of the meloxicam oral dosage forms, the compositions may be useful for the treatment of pain, including acute pain.

The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.

A method of treatment is disclosed, comprising administering a composition of Cyclodextrin and reduced, nanonized L-Glutathione to a patient in need of treatment, wherein the L-Glutathione molecule is non-acetylated, non-Esterified, and non-fatty acid attached.

The present invention relates to furazidin for vaginal use in the treatment of a bacterial vaginal infection. Preferably, the bacterial vaginal infection is caused by Gardnerella vaginalis and/or Atopobium vaginae bacteria.

Disclosed herein are compositions capable of enhanced delivery and absorption of biologically active agents when administered to a subject. Further disclosed are methods for increasing the in vivo absorption of biologically active agents.

The present disclosure describes simple, stable, and scalable antiviral therapeutic agent compositions that transform short-acting antiviral (e.g., anti-HIV) therapeutic agents that would otherwise require daily short-acting oral administration into long-acting injectable forms that lasts for many weeks per administration. A mixture of water-soluble and water-insoluble antiviral therapeutic agents can be present in the long-acting and drug-combination composition.

A solid water-dispersible composition of matter comprising at least one sugar, at least one polysaccharide and at least one surfactant and at least one lipophilic active pharmaceutical ingredient (API), the composition comprises a plurality of micrometric particles each comprising a plurality of lipophilic nanospheres with an average size in the range of 50-900 nm, the at least one lipophilic API is contained in the micrometric particles and is distributed inside and/or outside the lipophilic nanospheres at predetermined proportions, thereby providing an improved delivery of the at least one lipophilic API. A sugar particle comprising a porous sugar material and lipophilic nanospheres having average sizes between 50-900 nm so that the lipophilic nanospheres are comprised within the porous sugar material, the sugar particle comprises at least one edible sugar, at least one edible oil, at least one edible polysaccharide, at least one edible surfactant and at least one lipophilic API.